Skip to main
SLDB
SLDB logo

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 52%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences Inc. has projected that its product SGT-003 could potentially generate risk-adjusted revenues of $1 billion by 2033, with a significant increase from $90 million in 2028, indicating strong future growth prospects. Promising clinical data, such as an 8% improvement in cardiac function measured by left ventricular ejection fraction (LVEF) in certain patients, supports the efficacy of SGT-003 in treating Duchenne muscular dystrophy (DMD). Furthermore, the company's advancements in biomarker analysis related to muscle integrity suggest that ongoing developments in their therapeutic pipeline could enhance treatment options and expand the addressable market within the DMD sector.

Bears say

Solid Biosciences Inc. faces significant financial challenges primarily due to the uncertainty surrounding the regulatory approval of its lead product, SGT-003, which directly impacts risk-adjusted projections and can lead to downward revisions in the company's price targets. Additionally, the potential for manufacturing capacity constraints poses a risk to achieving sales expectations for SGT-003, which could further limit revenue generation. Compounding these issues, the gene therapy sector as a whole faces hurdles including complex regulatory pathways and unforeseen safety issues, which could impede the company's progress and ultimately affect its stock performance.

Solid Biosciences (SLDB) has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 52% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 21 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.